Bernstein bullish on India healthcare, sees $195 bn biopharma market by 2035 driven by innovation 'rainmakers'
New Delhi, May 24
Bernstein has initiated coverage on the India Healthcare sector with a positive view, calling it an "Innovation Power Decade" and projecting the country's biopharma industry to grow 4X to $195 billion over the next decade, driven by niche therapies and complex specialities.
A Bernstein report said that the brokerage sees six innovation "rainmakers" adding $70-75 billion to industry size. These include 505(B)(2) NDAs, orphan indications, drug-device combinations, drug repurposing in niche therapies, metabolic peptides, and RNA and cellular therapies such as CAR-T.
"We believe incremental innovation in six niches will produce Rainmakers for Indian biopharma," the report said.
Bernstein has initiated its coverage on six stocks in the pharmaceuticals and healthcare sector. The brokerage said Zydus Lifesciences is its top pick with an Outperform rating, alongside Lupin and Sun Pharma, also rated Outperform. Biocon and Mankind Pharma are non-consensus Underperform ideas, while Aurobindo Pharma is rated Market-Perform.
The firm said valuations for its Outperform names are trading "well below their ten-year average", adding that the market is pricing in domestic growth and US vanilla generics headwinds but not the rainmakers and Emerging Markets growth.
The broader thesis rests on three waves. First, the AI-led theme of 'live longer, look fitter, invest in healthcare' will drive innovation demand. Access to next-generation medicines, obesity control, mental well-being, nutraceuticals, preventive medicine like vaccines and wearables, personal hygiene, and digital healthcare will be key as the global workforce upgrades. Bernstein estimates these new modalities will add 100 million patients each year globally, creating a $400 billion incremental innovation opportunity.
Second, increasing health infrastructure penetration in emerging economies, an exponential rise in disposable income from AI leverage, and a lifestyle shift toward image consciousness will accelerate adoption. Third, quality culture and "Agenetic AI" gains will be the strongest catalysts for the innovation ecosystem.
"Indian Biopharma quality is on a transformation path and will anchor exports of these innovation medicines," the report noted. Bernstein's proprietary model suggests Indian biopharma will have the largest network of future-ready plants globally over the next decade. Gen AI adoption is expected to pivot to innovation efficiency, with three to four percentage points of profit margin upside from enterprise-wide AI use cases. R&D and operations are expected to drive 70% of this AI-led profitability unlock.
While Pharma Nifty multiples have accelerated to slightly above their ten-year average of 30.5x, Bernstein said policy uncertainties are winding down and valuations remain attractive for select names positioned to capture the innovation-led scale-up in earnings.
— ANI
Reader Comments
The 'live longer, look fitter' angle is spot on. But needam pannunga (a thought) - all this innovation sounds great on paper, but what about affordability? CAR-T therapy costs lakhs. If this is just for exports to US/Europe, then aam aadmi (common man) won't benefit. Hope the government ensures these 'rainmakers' also solve Indian healthcare problems like TB and antibiotic resistance.
As someone who worked in US pharma R&D, I've seen Indian companies step up massively in quality. The USFDA inspections are brutal but Indian firms have improved compliance dramatically. The $70-75 billion from rainmakers seems plausible if regulatory pathways stay supportive. However, Biocon being rated Underperform surprises me - they have biosimilars pipeline that could be a dark horse.
AI in pharma is the real game-changer. Imagine speeding up drug discovery from 10 years to 2-3 years! Gen AI for R&D and operations can indeed save 3-4% margins. But I worry about job displacement - my cousin is a lab technician and he's scared AI will replace him. Need to reskill our workforce for the AI era. Also, why is Mankind rated Underperform? Their OTC portfolio is rock solid.
Interesting report but I'm skeptical. Indian pharma has always promised 'innovation waves' but we mostly have copycats and me-too drugs. 505(B)(2) NDAs are incremental innovation at best - they're not blockbuster new chemical entities. For $195 billion market, we need fundamental discovery research, not just repurposing. Also, Bernstein's past predictions on Indian pharma have been hit-or-miss. Let's wait and watch.
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.